Tarsus Pharmaceuticals Inc (TARS)
Official siteHEALTHCARE • BIOTECHNOLOGY • NASDAQ
Market Cap: $3.96B
Last updated: Nov 17, 2026 at 11:06 AM ET
Tarsus Pharmaceuticals Inc (TARS) Stock Forecast
Analysts expect Tarsus Pharmaceuticals (TARS) to earn -$15.32 per share in the fiscal year ending Dec 31, 2026, on revenue of $741.50M. Of 10 analysts, 10 rate the stock Buy or Strong Buy, 0 Hold and 0 Sell or Strong Sell, for a consensus of Buy. Over the last 30 days, 1 estimate for the fiscal year ending Dec 31, 2026 was revised up and 0 down.
Analyst Ratings
Scoring Strong Buy as 1 and Strong Sell as 5, the 10 ratings average 1.90, inside the Buy band from 1.5 up to 2.5. Buy and Strong Buy make up 100% of the ratings.
| Rating | Analysts | Share |
|---|---|---|
| Strong Buy | 1 | 10.0% |
| Buy | 9 | 90.0% |
| Hold | 0 | 0.0% |
| Sell | 0 | 0.0% |
| Strong Sell | 0 | 0.0% |
- Consensus
- Buy
- Total analysts
- 10
Price Target
Analyst price targets are part of paid GNG plans. See plans
Annual Estimates
From the first fiscal year below to the second, the EPS consensus turns from a loss to a profit and revenue estimates rise 26.2%.
- Fiscal year ending Dec 31, 2026
- -$15.32
- EPS consensus, revenue $741.50M
- Fiscal year ending Dec 31, 2027
- $0.22
- EPS consensus, revenue $935.41M
- Next report
- Feb 22, 2027
- Estimated
EPS range
Revenue range
| Fiscal year ending | EPS consensus | EPS range | EPS analysts | Revenue consensus | Revenue range | Rev. analysts |
|---|---|---|---|---|---|---|
| Dec 31, 2026 | -$15.32 | -$15.58 to -$14.92 | 3 | $741.50M | $733.70M to $744.50M | 8 |
| Dec 31, 2027 | $0.22 | -$1.74 to $2.27 | 4 | $935.41M | $910.00M to $980.10M | 7 |
Quarterly Estimates
The EPS consensus falls from -$0.20 for the quarter ending Dec 31, 2026 to -$0.52 for the quarter ending Mar 31, 2027.
EPS range
Revenue range
| Quarter ending | EPS consensus | EPS range | EPS analysts | Revenue consensus | Revenue range | Rev. analysts |
|---|---|---|---|---|---|---|
| Dec 31, 2026 | -$0.20 | -$0.58 to $0.15 | 12 | $213.66M | $187.78M to $224.70M | 11 |
| Mar 31, 2027 | -$0.52 | -$0.65 to -$0.32 | 3 | $201.71M | $190.00M to $205.78M | 4 |
Estimate Revisions
Across the 3 periods below, the last 30 days brought 2 upward and 1 downward EPS revisions.
| Period | Up 30 days | Down 30 days |
|---|---|---|
| Fiscal year ending Dec 31, 2026 | 1 | 0 |
| Fiscal year ending Dec 31, 2027 | 1 | 0 |
| Quarter ending Mar 31, 2027 | 0 | 1 |
EPS Trend
Over the last 90 days, the EPS consensus for the fiscal year ending Dec 31, 2026 has worsened from -$2.13.
| Period | Now | 7 days ago | 30 days ago | 60 days ago | 90 days ago | Change |
|---|---|---|---|---|---|---|
| Fiscal year ending Dec 31, 2026 | -$15.32 | -$5.79 | -$5.77 | -$2.10 | -$2.13 | N/A |
| Fiscal year ending Dec 31, 2027 | $0.22 | -$0.50 | -$0.36 | $2.42 | $2.33 | -90.8% |
| Quarter ending Mar 31, 2027 | -$0.52 | -$0.60 | -$0.69 | $0.08 | $0.12 | N/A |
Frequently Asked Questions About TARS
What is the TARS stock forecast?
Consensus analyst estimates put Tarsus Pharmaceuticals's EPS at -$15.32 for the fiscal year ending Dec 31, 2026, on revenue of $741.50M. The consensus rating from 10 analysts is Buy.
How do analysts rate TARS stock?
Of 10 analysts covering Tarsus Pharmaceuticals, 1 rates it Strong Buy, 9 Buy, 0 Hold, 0 Sell and 0 Strong Sell, for a consensus of Buy.
What EPS do analysts expect from TARS next year?
For the fiscal year ending Dec 31, 2026, the consensus EPS estimate is -$15.32, with estimates from -$15.58 to -$14.92 from 3 analysts. For the fiscal year ending Dec 31, 2027, the consensus EPS estimate is $0.22, with estimates from -$1.74 to $2.27 from 4 analysts.
What revenue do analysts expect from Tarsus Pharmaceuticals next year?
For the fiscal year ending Dec 31, 2026, the consensus revenue estimate is $741.50M, with estimates from $733.70M to $744.50M. For the fiscal year ending Dec 31, 2027, the consensus revenue estimate is $935.41M, with estimates from $910.00M to $980.10M.
How many analysts cover TARS?
10 analysts rate Tarsus Pharmaceuticals stock, and 3 analysts estimate its EPS for the fiscal year ending Dec 31, 2026.
TARS pages: Overview, Earnings, Forecast, Financials, Valuation, Competitors